Dana–Farber Cancer Institute

New Study from AccessHope Affirms Cancer Subspecialist Reviews Improve Pancreatic Cancer Treatment Paths

Retrieved on: 
Tuesday, October 24, 2023
Neoplasm, Research, Cancer, City of Hope, Pancreas, Physician, Acupuncture & Electro-Therapeutics Research, Mortality, Prevalence, Dana–Farber Cancer Institute, City, Disease, LOS, Pancreatic cancer, Oncology, Therapy, Patient, Diagnosis, Pharmaceutical industry, Medical imaging, Hope

Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.

Key Points: 
  • Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.
  • Approximately 80-90% of patients with pancreatic cancer have unresectable tumors, meaning surgery is not a viable treatment option.
  • Determining the correct stage of disease at diagnosis and ensuring timely and coordinated multidisciplinary care is critical to attaining optimal outcomes for patients with pancreatic cancer.
  • The study on AccessHope's collaboration with NCI-Designated Comprehensive Cancer Centers evaluated data from 94 pancreatic cancer cases between August 2019 and December 2022.

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Exelixis, National Institutes of Health, NCI, ESMO, Progression-free survival, Alliance for Clinical Trials in Oncology, Physician, Congress, PFS, European Society for Medical Oncology, Dana–Farber Cancer Institute, Glomus tumor, Data monitoring committee, Disease, NET, National Cancer Institute, Oncology, CET, NETS, EXEL, Pnet, Patient, Bangladesh Technical Education Board, DSMB, Pharmaceutical industry, Medical imaging, Carcinoid

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET).
  • “Although progress has been made in recent years, there remains a critical need for new and effective therapies for patients with advanced neuroendocrine tumors.
  • Results from the CABINET study presented today at ESMO demonstrate that treatment with cabozantinib resulted in compelling improvements in PFS based both on local review and on independent blinded central radiology review.
  • The safety profile of cabozantinib observed in each cohort was consistent with its known safety profile; no new safety signals were identified.

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Retrieved on: 
Monday, October 16, 2023
Congress, European Society for Medical Oncology, ESMO, Oncology, SERD, Patient, Dana–Farber Cancer Institute, SAN, Pharmaceutical industry

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatment of metastatic breast cancer, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m.
  • ET on October 22, 2023
    Olema will host an investor conference call at 8:00 a.m.
  • ET on October 23, 2023
    SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced an oral presentation on the Phase 2 monotherapy study results of palazestrant (OP-1250), the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) for the treatment of metastatic breast cancer, at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • Details of the ESMO Congress 2023 mini oral session presentation are:
    Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients with advanced or metastatic ER-positive, HER2-negative breast cancer.

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Retrieved on: 
Monday, October 16, 2023
Cancer, MCC, Cell death, Therapeutic index, AACR, Dana–Farber Cancer Institute, St. Michael's Indian Residential School (Alert Bay), Safety, AML, Merkel-cell carcinoma, SMI, Therapy, Growth, TPD, MDM2, ALL, Skin, Conference, Feedback, International, Pharmaceutical industry, Vaccine

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023, in Boston, Massachusetts and will also be shared at the 10th International MDM2 Workshop taking place October 15-18, 2023, in Tokyo, Japan.

Key Points: 
  • p53 remains intact (wild type) in approximately 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
  • In preclinical studies, MDM2 degraders have demonstrated the ability to overcome the MDM2 feedback loop observed with MDM2 SMIs and rapidly induce cell death in sensitive p53 wild-type cancer cell lines, even with brief compound exposure.
  • This may enable an improved therapeutic index, which could result in a superior efficacy and safety profile over MDM2 SMIs.
  • These data demonstrate in vitro efficacy of an MDM2 degrader, KTX-049, against p53 wild-type MCC cell lines that was achieved with brief compound exposure.

Precede Biosciences Announces First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023

Retrieved on: 
Sunday, October 15, 2023
Congress, Doctor of Philosophy, Plasma, DNA, Oncology, ESMO, AR, Assistant, European Society for Medical Oncology, HER2, ER, Dana–Farber Cancer Institute, Medical device, Pharmaceutical industry, MD, Medicine

BOSTON, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission with a first release of groundbreaking scientific data at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • BOSTON, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission with a first release of groundbreaking scientific data at the European Society for Medical Oncology (ESMO) Congress 2023.
  • The meeting will be held October 20 – 24 in Madrid, Spain, and virtually.
  • The oral presentation will focus on data generated using the company’s first-in-class liquid biopsy platform that reveals disease-defining transcriptional biology.
  • The presentation will be given by Sylvan Baca, MD, PhD, Co-Founder of Precede Biosciences and Assistant Professor of Medicine at Dana-Farber Cancer Institute.

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023
Clinical Science (journal), Ludwig Maximilian University of Munich, Cancer, Dana–Farber Cancer Institute, Department of Medicine – University of Pamplona, Faculty, Research, Clinical, Therapy, Case Western Reserve University, Hospital, Nature, Melanoma, Journal, Nivolumab, Carcinoma, Brigham and Women's Hospital, Harvard Medical School, Clinical trial, Associate, American Journal of Clinical Oncology, Principal investigator, Neoplasm, Patient, Vaccine, Pharmaceutical industry, New York University, Medicine

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform

Retrieved on: 
Thursday, October 5, 2023
Congress, Cancer, Medicine, MBA, Drug development, Plasma, Biology, Breast cancer, Bandwidth (signal processing), Qatar Investment Authority, Bristol Myers Squibb, Dana–Farber Cancer Institute, MD, DNA, Oncology, ESMO, RUO, Doctor of Philosophy, QIA, Initiative, Molecular biology, European Society for Medical Oncology, Spacecraft, Liquid biopsy, HER2, Patient, Eli Lilly and Company, Medical imaging, Pharmaceutical industry

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences emerges from stealth today with a breakthrough, comprehensive, blood-based approach to revealing disease-defining transcriptional biology – a first for the diagnostic field. Precede’s genome-wide platform simultaneously explores the dynamic, feature-rich space of gene promoters, gene enhancers, and the DNA methylome from a single milliliter (1mL) of plasma. Precede is actively partnering with drug developers to accelerate the development of precision medicines by identifying the biology associated with response and resistance to treatment and by identifying novel targets mechanistically linked to disease biology. In parallel, Precede is developing blood-based clinical tests to advance precision use of cancer medicines in clinical practice. Precede’s platform is available to drug developers and academic researchers as a Research Use Only (RUO) platform as of today. Since inception, Precede has secured $57M in backing from leading venture and private equity investors.

Key Points: 
  • In parallel, Precede is developing blood-based clinical tests to advance precision use of cancer medicines in clinical practice.
  • Precede’s platform is available to drug developers and academic researchers as a Research Use Only (RUO) platform as of today.
  • Genomic liquid biopsy (LBx) technologies have had a tremendous impact on cancer care over the last decade.
  • "Existing liquid biopsy technologies have impacted millions of patients with cancer over the last decade, and the precision medicine application space for Precede transcends that of even the most successful of these liquid biopsy technologies, creating a significant opportunity for us to impact the practice of medicine."

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Congress, Neoplasm, Multimedia, Cancer, Senior, Doctor of Philosophy, HNSCC, MD, ESMO, B-cell lymphoma, Carcinoma, CAR, Head, TNBC, European Society for Medical Oncology, MBC, Patient, Dana–Farber Cancer Institute, Pharmaceutical industry, Sacituzumab govitecan, Axicabtagene ciloleucel

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.
  • Kite will also present analyses supporting the use of Yescarta® (axicabtagene ciloleucel) in relapsed/refractory large B-Cell lymphoma (LBCL).
  • View the full release here: https://www.businesswire.com/news/home/20231015111917/en/
    “Our data at ESMO 2023 reflect a broad clinical development program in difficult-to-treat cancers,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
  • “We believe our data will help further clinicians’ understanding of when to use Yescarta in these patients and reinforce confidence in CAR T-cell therapies overall.”

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Retrieved on: 
Saturday, October 14, 2023
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Pharmacokinetics, KRAS, RAMP, NSCLC, AACR, Dana–Farber Cancer Institute, ORR, Toxicity, Safety, Lung cancer, Mutation, RAS, George M. Low Center for Industrial Innovation, Cancer, Clinical research, DLT, Harvard Medical School, Verastem Oncology, Associate, MAPK, Conference, Patient, Pharmaceutical industry, Medicine

The results will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • The results will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 11-15, 2023 in Boston, Massachusetts.
  • The pharmacokinetic profile of avutometinib in combination with sotorasib was similar to results in monotherapy studies.
  • Enrollment of patients with KRAS G12C-mutant NSCLC who are either naïve to or previously treated with a KRAS G12C inhibitor is ongoing in the expansion phase of RAMP 203.
  • “Given KRAS G12C mutations are the most common KRAS mutation in NSCLC and acquired mutations and amplifications occur upon clinical progression to KRAS G12C inhibitor monotherapy, the results of the RAMP 203 trial are important in understanding potential new treatment approaches for patients.”

Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Other Health, National Academy of Medicine, Acute myeloid leukemia, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, Research, Francis Crick Institute, Bristol Myers Squibb, Harvard University, NAM, The Emperor of All Maladies, Cell biology, Medicine, National academy, Pulitzer Prize, Therapy, Immunotherapy, Genetics, Mukherjee, Assistant, Dana–Farber Cancer Institute, ARD International Music Competition, CRUK, Disease, Dana, National Academy of Science and Technology, Tony Faeth, Pharmaceutical industry

Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).

Key Points: 
  • Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).
  • "Dr. Mukherjee's induction into the National Academy of Medicine reaffirms Faeth Therapeutics' dedication to unparalleled scientific rigor and innovation.
  • In the National Academy of Medicine, members are elected by their colleagues as a testament to their exceptional accomplishments.
  • Being inducted into the academy represents one of the most prestigious accolades within the realm of medicine.